Effect of high dose methylprednisolone pulse therapy followed by oral prednisolone administration on the production of anti-TSH receptor antibodies and clinical outcome in Graves' disease.
Little is known about the immunosuppressive effect of glucocorticoids on TSH receptor antibodies. We observed the long-term prognosis and serum TSH binding inhibitor immunoglobulin (TBII) levels in patients with Graves' ophthalmopathy who had received intravenous methylprednisolone pulse therapy (pulse therapy) followed by oral prednisolone administration in order to ascertain how long the immunosuppressive effect of glucocorticoids continued. This is the first report on the effect of pulse therapy on Graves' disease outcome. We observed 67 patients who were treated by antithyroid drugs (ATD) alone for 2 years after pulse therapy. TBII was evaluated before and 3, 6, 12, 18, and 24 months after pulse therapy. The mean TBII decreased significantly 3 months after pulse therapy (p<0.001), and was maintained until 24 months. There were 24 patients whose TBII was positive (>15%) at 24 months, in whom the mean TBII decreased significantly 3 to 6 months after pulse therapy (p<0.001), but increased again at 12 to 24 months (p<0.05). Thus, the immunosuppressive effect of glucocorticoids may be lost at 12 months after pulse therapy in these patients. The remission rate in the pulse therapy group was 40.98%, and that of the control patient group was 48.57%. There was no significant difference between the two. These results suggest that the immunosuppressive effect of pulse therapy was temporary, and that pulse therapy did not increase remission rate of Graves' disease.
Kubota
Sumihisa
S
Kuma Hospital, Kobe, Japan.
Ohye
Hidemi
H
Nishihara
Eijun
E
Kudo
Takumi
T
Ito
Mitsuru
M
Fukata
Shuji
S
Amino
Nobuyuki
N
Kuma
Kanji
K
Miyauchi
Akira
A
D000284:Administration, Oral; D000328:Adult; D001323:Autoantibodies / Q000097:blood*; D016022:Case-Control Studies; D005260:Female; D006111:Graves Disease / Q000097:blood / Q000188:drug therapy* / Q000276:immunology*; D049970:Graves Ophthalmopathy / Q000097:blood / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D018828:Immunoglobulins, Thyroid-Stimulating; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage* / Q000627:therapeutic use; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage* / Q000627:therapeutic use; D020551:Pulse Therapy, Drug; D011989:Receptors, Thyrotropin / Q000097:blood*; D012074:Remission Induction; D013997:Time Factors; D016896:Treatment Outcome
D001323:Autoantibodies; D018828:Immunoglobulins, Thyroid-Stimulating; D011989:Receptors, Thyrotropin; C094372:thyrotropin-binding inhibitory immunoglobulin; D007073:Immunoglobulin E; D011239:Prednisolone; D008775:Methylprednisolone